This article was downloaded by: [University of California Santa Cruz] On: 11 November 2014, At: 03:39 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lsyc20</u>

A Convenient, Large Scale Synthesis of trans-(+)-Sobrerol

Qiuan Wang^a, Yanlin Li^a & Qingqi Chen^b

^a College of Chemistry and Chemical Engineering, Hunan University, Changsha, P.R. China ^b Biomarin Pharmaceutical Inc., Vancouver, Canada Published online: 17 Aug 2006.

To cite this article: Qiuan Wang, Yanlin Li & Qingqi Chen (2003) A Convenient, Large Scale Synthesis of trans-(+)-Sobrerol, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 33:12, 2125-2134, DOI: <u>10.1081/SCC-120021040</u>

To link to this article: http://dx.doi.org/10.1081/SCC-120021040

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions



MARCEL DEKKER, INC. • 270 MADISON AVENUE • NEW YORK, NY 10016

©2003 Marcel Dekker, Inc. All rights reserved. This material may not be used or reproduced in any form without the express written permission of Marcel Dekker, Inc.

SYNTHETIC COMMUNICATIONS[®] Vol. 33, No. 12, pp. 2125–2134, 2003

A Convenient, Large Scale Synthesis of *trans-*(+)-Sobrerol

Qiuan Wang,¹ Yanlin Li,¹ and Qingqi Chen^{2,*}

¹College of Chemistry and Chemical Engineering, Hunan University, Changsha, P.R. China ²Biomarin Pharmaceutical Inc., Vancouver, Canada

ABSTRACT

A convenient and highly efficient synthesis of optically pure *trans*-(+)-sobrerol (1), starting from methyl 3,5-dihydroxy-4-methyl benzoate 2 in 8 steps with overall yield 26%, is reported. The key intermediate 4 is prepared in remarkably high yield by selectively esterification of 3 using lipase as catalyst. A critical step to stereoselectively inverse the configuration of 7 is realized under Mistunobu conditions.

2125

DOI: 10.1081/SCC-120021040 Copyright © 2003 by Marcel Dekker, Inc. 0039-7911 (Print); 1532-2432 (Online) www.dekker.com

^{*}Correspondence: Qingqi Chen, Biomarin Pharmaceutical Inc., 2386 East Mall, Vancouver, BC, V6T 1Z3, Canada; E-mail: qchen@synapse-tech.com.



2126

Wang, Li, and Chen

INTRODUCTION

The *trans*-(+)-sobrerol (1, *trans-p*-menth-6-ene-2,8-diol) is a wellknown mucolytic drug.^[1] Many other important biological activities of this compound have recently been found and attracted increasing attention.^[2–3] For example, sobrerol was found to have chemopreventive activity to induce tumor cell apoptosis, and/or to inhibit the posttranslational isoprenylation of cell growth-regulating proteins,^[2] and to inhibit farnesyltransferase regulating the development of pulmonary hypertension.^[3] More interestingly, *trans*-sobrerol (1) is also a versatile chiral tool in the asymmetric synthesis of a number of natural products.^[4]

trans-(\pm)-Sobrerol is commercially available from Aldrich-Sigma. However, reports on the preparation of its optical active isomer, *trans*-(\pm)-sobrerol, are scarce. Literature methods on the synthesis of compound **1**, including acid-catalyzed cleavage^[4] or RuCl₃ mediated ring-open^[5] of (\pm)-2,3-epoxy-*cis*-pinane in aqueous systems, and kinetic resolution of (\pm)-*trans*-sobrerol by lipase-catalyzed acetylation,^[1] suffer from either low yield or poor optical purity, and are not suitable for large scale preparation. Herein, we wish to report a convenient and highly efficient stereogenic synthesis of optically pure **1** using readily available starting materials (Sch. 1).

RESULTS AND DISCUSSION

Methyl 3.5-dihydroxy-4-methyl benzoate (2) is converted in 65% yield to *all-cis*-3.5-dihydroxy-4-methyl-1-(methoxycarbonyl)cyclohexane (3) by Rh/Al₂O₃ catalyzed hydrogenation as described previously,^[6,7] which is then esterified using vinyl acetate to generate 93% enantiomerically pure monoacetate (4) under enzyme catalyzed condition using lipase (Ps. Fluorescens, Fluka).

The enantiomeric excess is determined by subcritical fluid chromatography (SFC).^[8] The absolute configurations of **3** and **4** could be deduced by the structure of *cis*-(–)-sobrerol **11**, which is prepared in two steps from **4** as outlined in Sch. 2. Compound **4** is dehydrated under Mitsunobu conditions,^[9] and converted to the corresponding cyclohexene **10**, and further to cis-(-)-sobrerol, **11**, upon reaction with MeMgBr.^[10]

Treating **4** *tert*-butyldiphenylsilyl chloride (TBDPS-chloride) and subsequently with K_2CO_3 in dry methanol, the expected TBDPS ether **5** is obtained in 84% yield, which is dehydrated under Mitsunobu conditions to give the corresponding TBDPS-cyclohexenol **6** in 92% yield. Removal of the TBDPS group of **6** using tetrabutylammonium fluoride (TBAF) in



Optically Pure trans-(+)-Sobrerol



Scheme 1. Reagents and conditions: a) H_2 , 5% Rh/Al₂O₃, ethanol, 105 \Box for 24 h, 65%. b) lipase (Ps. fluorescens), r.t. for 72 h, 93%. c) (1) *t*-BuPh₂SiCl, imidazole, DMAP, DMF, r.t. for 20 h. (2) K₂CO₃, MeOH, r.t. for 7 h, 84%. d) Ph₃P, DEAD, THF, r.t. for 15 h, 92%. e) TBAF, THF, r.t. for 20 h, 90%. f) *p*-Nitrobenzoic acid, Ph₃P, DEAD, toluene, r.t. for 9 h, 78%. g) K₂CO₃, MeOH, r.t. for 8h, 93%. h) MeMgBr, THF, $-78\Box$ for 6 h, 85%.



Scheme 2. Reagents and conditions: a) Ph₃P, DEAD, THF, r.t. for 15h, 92%.
b) MeMgBr, THF, -78□ for 6h, 86%.

THF at room temperature gives 7 in 90%. The key conversion to 8 is achieved in 78% yield using triphenylphosphine and *p*-nitrobenzoic acid in the presence of diethylazodicarboxylate at room temperature for 9 h. Deprotection of the *p*-nitrobenzoate ester 8 with anhydrous K_2CO_3 and

2127



2128

Wang, Li, and Chen

dry MeOH give **9** in 93% yield, which is further to converted the target compound, *trans*-(+)-sobrerol **1** in 85% yield with ee > 99% upon treatment with MeMgBr in THF at $-78\Box$. The structure of **1** is confirmed by NMR, MS, combustion analysis, which are identical with the literature report.^[1,2]

In summary, we here have reported a very convenient, highly efficient method for the synthesis of trans-(+)-sobrerol (1), which is suitable for larger scale synthesis.

EXPERIMENTAL SECTION

Column chromatography was performed on silica gel. HPLC separations were performed on a Knauer 64 or a Kontron 420 delivery system with RI detection. Optical rotations were measured with a Perkin-Elmer 421 polarimeter. IR spectra were recorded on a Perkin-Elmer FTIR-1600 spectrometer, mass spectra on a HP-5988 Spectrometer. The ¹H NMR spectra were recorded at 500 MHz (Brucker AN-500), the ¹³C NMR Spectra at 50 MHz (Varian Gemini-200). The chemical shifts (δ) are reported in parts per million with reference at 0 ppm (Me₄Si) or 7.26 ppm (CHC1₃) for the proton and at 77.0 ppm (centered on the signal of CDCl₃) for the carbon. Elemental analyses were carried out on a Perkin-Elmer 240B microanalyzer. Enantiomeric excess (ee) values are determined by SFC (Column chiralpak AD, Diacel, Japan, eluent CO₂ modified with 5% MeOH). All solvents and reagents are purchased from Aldrich, Sigma, or Fluka. Ester **3** is prepared according to the previous reports.^[6,7]

(1R,3S,4S,5R)-5-Acetoxy-3-hydroxy-4-methyl-1-(methoxycarbonyl)cyclohexane (4)

A mixture of diol **3** (1.0 g, 5.5 mmol) and lipase (Ps. fluorescens) (650 mg, 42.5 U/mg) in vinyl acetate (30 mL) was stirred in the dark at room temperature. The reaction was monitored by TLC (H₃PO₄/12MoO₃ solution as indictor). After 72 h, the reaction mixture was filtered through a pad of celite. The filtrate was concentrated, and purified on a short (2.5 cm × 10 cm) silica gel column (*i*-octane/EtOAc, v/v, 5/5) to give a colorless oil (11.8 g, 93%). R_f 0.36 (*i*-octane/EtOAc, v/v, 5/5). $[\alpha]_D^{25} = -21.9$ (c 0.81, CHCl₃), ee \geq 99%. IR (film): $\nu = 3437$, 2953, 1730, 1472, 1439, 1365, 1242, 1197, 1178, 1078, 1026, 981,



Optically Pure trans-(+)-Sobrerol

875 cm⁻¹. ¹H NMR (500 MHz, CDCl₃, δ = 4.8 (m, 1H), 3.8 (m, 1H), 3.69 (s, 3H), 2.4 (m, 1H), 2.30 (d, *J* = 6.4 Hz, 1H), 2.05 (s, 3H), 1.9 (m, 2H), 1.8 (m, 3H), 0.96 (d, *J* = 7.0 Hz, 3H) ppm. ¹³C NMR (50 MHz, CDCl₃, δ = 174.6, 170.3, 72.1, 69.6, 52.0, 38.0, 37.6, 30.5, 27.3, 21.2, 6.21 ppm. MS: *m*/*z* = (%): 231 (M⁺+1,1), 213 (2), 199 (4), 186 (5), 170 (15), 152 (21), 127 (60), 111 (70), 93 (75), 87 (25), 82 (20), 43 (100). Anal. Calcd. for C₁₁H₁₈O₅, required: C, 57.38; H, 7.88%. Found: C, 57.21; H, 7.95%.

(1S,R,4R,5S)-5-*t*-Butyldiphenylsilyloxy-3-hydroxy-4-methyl-1-(methoxy-carbonyl)cyclochexane (5)

To a stirred solution of 4 (8.1 g, 35.2 mmol), imidazole (7.2 g, 105.7 mmol) and DMAP (2.2 g) in dry DMF (120 mL) was added dropwise *tert*-butyldiphenyl silyl chloride (TBDPSCl, 18 mL. 70.4 mmol). The mixture was stirred for 20h at room temperature before pouring into water-EtOAc (600 mL, v/v, 1/1). The organic layer was separated and then the aqueous layer was extracted with EtOAc ($200 \text{ mL} \times 3$). The combined extracts were washed with brine $(150 \times 3 \text{ mL})$, dried over anhydrous MgSO₄ and concentrated to give the crude product, which was then dissolved in 150 mL dry MeOH, and treated with K_2CO_3 (600 mg). The mixture was stirred at room temperature for 10 min. before the second portion K_2CO_3 (380 mg) was added. The mixture was allowed to stir for 6h at room temperature, then partitioned with EtOAc (300 mL) and water (200 mL). The organic phase was separated and aqueous phase was extracted with EtOAc ($300 \text{ mL} \times 3$). The organic phase and extracts were combined, dried over anhydrous magnesium sulfate, and concentrated under vacuum to give the crude product, which was further purified by flash chromatography over silica gel (i-octane/EtOAc, v/v, 9/1) to offer 5 (6.9 g, 98%) as a colorless oil. R_f 0.16 (*i*-octane/EtOAc, v/v, 8/2), $[\alpha]_D^{25} = +33.0$ (c 0.62, CHCl₃). IR (film): $\nu = 3448, 2954, 2858, 1737, 1654, 1472, 1362, 1279, 1240, 1173, 1008,$ 852, 822, 795, 741, 702, 611 cm^{-1} . ¹H NMR (500 MHz, CDCl₃, $\delta = 7.6$ (m, 4H), 7.4 (m, 2H), 7.4 (m, 4H), 3.70 (m, 1H), 3.64 (s, 3H), 3.5 (m, 1H), 2.2 (m, 1H), 2.1 (m, 1H), 1.8 (m, 1H), 1.69 (t, J=8.9 Hz, 2H), 1.56 (q, J=12.4 Hz, 1H), 1.37 (d, J=5.3 Hz, 1H), 1.06 (s, 9H), 1.02(d, J = 7.0 Hz, 3H). MS: m/z (%): 409 (1), 369 (7), 337 (7), 309 (5), 291 (35), 199 (100), 156 (85), 181 (17), 153 (34), 121 (23), 93 (68), 57 (47). Anal. Calcd. for C₂₅H₃₄O₄ Si, required: C, 70.38; H, 8.03%. Found: C, 70.55; H, 7.91%.

2129



2130

Wang, Li, and Chen

(4S,6S)-6-*t*-Butyldiphenylsilyloxy-1-methyl-4-(methoxycarbonyl)cyclohexene (6)

To a stirred solution of 5 (19.0 g, 45.0 mmol) and Ph_3P (57.7 g, 220 mmol) in THF (300 mL) at r.t., was added dropwise diethylazodicarboxylate (DEAD, 41 mL, 220 mmol). After stirring overnight at room temperature, the solution was concentrated. The residue was purified by flash chromatography over silica gel (ioctane/EtOAc, v/v, 95/5) to afford the expected compound 6 (16.7 g, 92%) as colorless oil. R_f 0.31 (*i*-octane/ EtOAc, 95:5), $[\alpha]_D^{25} = +81.8$ (c 1.52, CHCl₃). IR (film): v = 2952, 2857, 1738, 1589, 1472, 1429, 1362, 1308, 1247, 1169, 1111, 1062, 1000, 934, 821, 740, 703 cm⁻¹. ¹H NMR $(500 \text{ MHz}, \text{ CDCl}_3, \delta = 7.7 \text{ (m, 10H)}, 5.4 \text{ (m, 1H)}, 4.24 \text{ (s, 1H)}, 3.59 \text{ (s, 2H)}, 3.59 \text{ (s, 2H)},$ 1H), 2.4 (m, 1H), 2.3 (m, 3H), 1.7 (m, 1H), 1.66 (s, 3H), 1.07 (s, 9H) ppm 13 C NMR (50 MHz, CDCl₃), $\delta = 175.2$, 137.5, 136.1, 134.4, 133.7, 129.6, 127.6, 121.9, 71.4, 51.6, 38.9, 35.2, 27.9, 27.1, 20.2, 19.5 ppm MS: m/z (%): 408 (M⁺, 1), 354 (8), 351 (M⁺-57, 20), 299 (5), 273 (6), 213 (100), 183 (75), 137 (70). Anal. Calcd. for C₂₅H₃₂O₃ Si, required: C, 73.49; H, 7.89%. Found: C, 73.25; H, 7.74%.

(4S,6S)-6-Hydroxyl-1-methyl-4-(methoxycarbonyl)cyclohexene (7)

To a stirred solution of 6 (13.7 g, 34 mmol) in THF (200 mL) was added TBAF (180 mL, 1M in THF). The mixture was stirred for 20 h at room temperature. THF was evaporated, the residue was purified by flash chromatography over silica gel (i-octane/EtOAc, v/v, 8/2) to give the desired compound 7 (5.2 g, 90%) as a colorless oil. $R_{\rm f}$ 0.18 (*i*octane/EtOAc, v/v, 8/2). To a stirred solution of 6 (13.7 g, 34 mmol) in THF (200 mL) was added TBAF (180 mL, 1 M in THF). The mixture was stirred for 20h at room temperature. THF was evaporated, the residue was purified by flash chromatography over silica gel (ioctane/EtOAc, v/v, 8/2) to give the desired compound 7 (5.2 g, 90%) as a colorless oil. R_f 0.18 (*i*-octane/EtOAc, v/v, 8/2). $[\alpha]_D^{25} = +16.8$ (c 0.66, CHCl₃). IR (film): $\nu = 3432$, 2951, 2850, 1735, 1455, 1435, 1382, 1247, 1185, 1170, 1035, 925 cm⁻¹. ¹H NMR (500 MHz, CDCl₃, $\delta = 5.45$ (t, J=1.5 Hz, 1H), 4.08 (t, J=6.2 Hz, 1H), 3.68 (s, 3H), 2.7 (m, 1H),2.3 (m, 3H), 2.15 (brs, 1H), 1.9 (m, 1H), 1.78 (s, 3H). MS m/z (%): $170 (M^+, 3), 152 (20), 137 (15), 111 (30), 93 (100), 77 (30), 43(50).$ Anal. Calcd. for C₉H₁₄O₃ (170.21): C, 63.51; H, 8.29%. Found: C, 63.31; H, 8.40%.



Optically Pure trans-(+)-Sobrerol

(4S,6R)-1-Methyl-6-(4'-nitrobenzoyloxy)-4-(methoxycarbonyl)cyclohexene (8)

To a stirred solution of 7 (3.5 g, 16.5 mmol), 4-nitrobenzoic acid (3.04 g, 18.2 mmol) and Ph₃P (4.76 g, 18.2 mmol) in THF (200 mL) was added dropwise DIAD (34mL, 18.2mmol) over a period of 30min at $0-10\Box$, then the reaction mixture was stirred at room temperature for 9 h before filtering through a pad of celite and washing with ethyl acetate. The yellow filtrate was evaporated. The residue was further purified by flash chromatography over silica gel (i-octane/EtOAc, v/v, 9/1) to afford 4-nitrobenzoate ester 8 (5.12 g, 78%) as a colorless oil. R_f 0.3 (*i*octane/EtOAc, v/v, 9/1). $[\alpha]_D^{25} = +281.5$ (c 1.38, CHCl₃), IR (film): v = 2950, 1719, 1607, 1527, 1436, 1343, 1267, 1196, 1167, 1101, 1013, 946, 921, 873, 848, 720 cm⁻¹. ¹H NMR (500 MHz, CDCl₃ $\delta = 8.29$ (d, J = 7.9 Hz, 2H), 8.22 (d, J = 7.9 Hz, 2H), 5.79 (brs, 1H), 5.54 (s, 1H), 3.69 (s, 3H), 2.8 (m, 1H), 2.45 (d, J = 17.8 Hz, 1H), 2.32 (d, J = 11.6 Hz, 1H), 2.25 (t, J = 13.2 Hz, 1H), 2.0 (m, 1H), 1.75(s, 3H) pp. ¹³C NMR (50 MHz, CDCl₃): δ = 175.5, 164.5, 150.8, 135.9, 127.1, 123.7, 77.8, 77.2, 76.5, 71.2, 52.0, 35.1, 28.0, 20.9 ppm. MS *m*/*z* (%): 319 (M⁺, 1), 259 (8), 152 (20), 150 (75), 121 (20), 93 (100). 77 (40), 50 (30). Anal. Caled. for C₁₆H₁₇NO₆, required: C, 60.18; H, 5.37; N, 4.39%. Found: C, 59.87; H, 5.11; N, 4.01%.

(4S,6R)-6-Hydroxyl-1-methyl-4-(methoxycarbonyl)cyclohexene (9)

To the solution of 4-nitrobenzoate ester 8 (5.0 g, 15.7 mmol) in MeOH (200 mL) was added K_2CO_3 (108 g, 7.85 mmol). The mixture was stirred at room temperature for 8h before partitioning with EtOAc (300 mL) and water (200 mL). The organic layer was separated, the aqueous layer was extracted with EtOAc $(3 \times 100 \text{ mL})$. The combined organic layer and extracts were washed with brine $(3 \times 60 \text{ mL})$, dried over anhydrous magnesium sulfate and concentrated under vacuum. The residue was purified by flash chromatography over silica gel (*i*octane/EtOAc, v/v, 8/2) to yield the expected product 9 (2.48 g, 93%) as a colorless oil. $R_f 0.22$ (*i*-octane/EtOAc, v/v, 8/2). $[\alpha]_D^{25} = +156.3$ (c 0.6, CHCl₃). IR (film): v = 3406, 2952, 1734, 1437, 1250, 1197, 1053, 966, 809 cm^{-1} . ¹H NMR (500 MHz, CDCl₃): $\delta = 5.56$ (q, J = 1.4 Hz, 1H), 4.05 (brs, 1H), 3.69 (s, 3H), 2.7 (m, 1H), 2.2 (m, 2H), 1.79 (m, 4H). 1.61 (s, 1H). ¹³C NMR (50 MHz, CDCl₃): $\delta = 176.0$, 134.4, 123.8, 67.3, 51.8, 34.3, 34.2, 27.9, 20.8 ppm, MS *m*/*z* (%): 170 (M⁺,15), 139 (15), 120 (10), 110 (70), 95 (100), 77 (70), 67 (50), 55 (80), 43 (70). Anal. Calcd.

2131



2132

Wang, Li, and Chen

for C₉H₁₄O₃ (170.21): required: C, 63.51; H, 8.29%. Found: C, 63.42; H, 8.37%.

(4S,6R)-6-Hydroxyl-4-(1-hydroxyisopropyl)-1methylcyclohexene (1) (*trans*-(+)-Sobrerol) (1)

To a stirred solution of 9 (2.5 g, 11.8 mmol) in THF (60 mL) at $-78\Box$ was added dropwise MeMgBr (66 mL, 3.0 M in Et₂O). The mixture was stirred for 6 h at $-78 \square$ before slowly warming up room temperature. The mixture is further stirred overnight at room temperature. The reaction was quenched with aqueous saturated NH₄Cl (50 mL) and extracted with EtOAc $(3 \times 200 \text{ mL})$. The combined organic layers were washed with brine $(3 \times 100 \text{ mL})$, dried over anhydrous magnesium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (*i*-octane/EtOAc, v/v, 6/4) and crystallized from CH₂Cl₂ to give the desired compound 1 (1.68 g, 85%) as colorless needle. m.p. 130–132 \Box , R_f 0.22 (*i*-octane/EtOAc, v/v, 1/1) $[\alpha]_D^{25} = +133.4$ (c 0.31, CHCl₃), $(\text{film}) \square \nu = 3274 \square 2973 \square 1629 \square 1468 \square 1425 \square 1376 \square$ $ee \ge 99\%$. IR $1294 \square 1251 \square 1156 \square 1052 \square 984 \square 920 \square 824 \square 761 \square 662 \square 611 \square 468 \text{ cm}^{-1}$. ¹H NMR (500 MHz, CDCl₃): $\delta = 5.58$ (q, J = 1.4 Hz, 1H), 4.05 (s, 1H), 2.1 (m, 1H), 2.01 (dd, J = 13.4, 1.4 Hz, 1H), 1.80(s, 3H), 1.8 (m, 1H), 1.54 (br)s, 2H),1.4 (m, 2H), 1.22 (s, 2H), 1.19 (s, 3H) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 133.5, 125.5, 72.4, 68.8, 39.0, 32.9, 27.7, 27.2, 21.0 ppm. MS: m/z (%): 152(M⁺-18,6), 149 (7), 137 (10), 119 (5), 109 (55), 97 (8), 95 (15), 79 (50), 69 (25), 59 (90), 55 (35), 43 (100). Anal. Calcd for $C_{10}H_{18}O_2$ (170.25): C, 70.55; H, 10.66%. Found: C, 70.61; H, 10.85%.

(4R,6R)-6-Acetoxy-1-methyl-4-(methoxycarbonyl)cyclohexene (10)

To a stirred solution of monoacetate 4 (420 mg 1.67 mmol) and Ph₃P (1.32 g, 5.02 mmol) in THF (30 mL) at room temperature was added dropwise DIAD (0.93 mL, 5.02 mmol). After stirring overnight at room temperature, the solution was concentrated under vacuum. The residue was purified by column chromatography over silica gel (*i*-octane/EtOAc, v/v, 95/5) to afford **10** (356 mg, 92%) as a colorless oil. To a stirred solution of monoacetate **4** (420 mg, 1.67 mmol) and Ph₃P (1.32 g, 5.02 mmol) in THF (30 mL) at room temperature was added dropwise DIAD (0.93 mL, 5.02 mmol). After stirring overnight at room temperature, the solution was concentrated under vacuum. The residue was purified by column chromatography over silica gel (*i*-octane/EtOAc, v/v, 95/5) to afford **10** (356 mg, 92%) as a colorless oil. To a stirred solution of monoacetate **4** (420 mg, 1.67 mmol) and Ph₃P (1.32 g, 5.02 mmol) in THF (30 mL) at room temperature was added dropwise DIAD (0.93 mL, 5.02 mmol). After stirring overnight at room temperature, the solution was concentrated under vacuum. The residue was purified by column chromatography over silica gel (*i*-octane/EtOAc, the solution was concentrated under vacuum. The residue was purified by column chromatography over silica gel (*i*-octane/EtOAc, the solution was concentrated under vacuum. The residue was purified by column chromatography over silica gel (*i*-octane/EtOAc, the solution was concentrated under vacuum. The residue was purified by column chromatography over silica gel (*i*-octane/EtOAc, the solution chromatography over silica gel (*i*-octan



2133

©2003 Marcel Dekker, Inc. All rights reserved. This material may not be used or reproduced in any form without the express written permission of Marcel Dekker, Inc.

Optically Pure trans-(+)-Sobrerol

v/v, 95/5) to afford **10** (356 mg, 92%) as a colorless oil. R_f 0.35 (i-octane/EtOAc, v/v, 9/1). $[\alpha]_D^{25} = -50.5$ (c 0.72, CHC1₃) IR (film): $\nu = 3070$, 2951, 2850, 1736, 1456, 1436, 1370, 1343, 1239, 1170, 1074, 1028, 987, 932 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): $\delta = 5.48$ (d, J = 1.5 Hz, 1H), 5.35 (br s, 1H), 3.67 (s, 3H), 2.7 (m, 1H), 2.4 (m, 3H), 2.05 (s, 3H), 1.8 (m, 1H), 1.63 (s, 3H) ppm. ¹³C NMR (50 MHz, CDCl₃): $\delta = 174.7$, 170.8, 132.6, 124.7, 71.1, 51.7, 37.6, 31.0, 27.3, 21.0, 19.1 ppm. MS *m*/*z* (%): 212 (M⁺□5) □199 (8), 184 (8), 170 (95), 152 (85), 139 (62), 121 (45), 111 (75), 93 (100), 77 (80). Anal. Calcd. for C₁₁H₁₅O₄, required: C, 62.55; H, 7.16%. Found: C, 62.18; H, 7.23%.

(4R,6R)-6-Hydroxy-4-(1-hydroxyisopropyl)-1methylcyclohexene (*cis*-(-)-Sobrerol (11)

This compound was prepared as the same method as described for compound 1. Yield: 86%. M.p. 109–110 \square . $R_{\rm f}$ 0.18 (*i*-octane/EtOAc, v/v, 5/5). $[\alpha]_D^{25} = -20.1$ (c 0.72, CHCl₃) {lit.^[7] $[\alpha]_D^{25} = -16$ }. IR (film): $\nu = 3283$, 2969, 2944, 2886, 2849, 1454, 1383, 1320, 1256, 1167, 1148, 1109, 1037, 974, 922 cm^{-1.} ¹H NMR (500 MHz, CDCl₃): $\delta = 5.47$ (*t*, *J* = 1.45 Hz, 1H), 4.16 (brs, 1H), 2.2 (m, 1H), 2.05 (m, 1H), 1.89 (m, 1H), 1.74 (s, 3H), 1.6 (m, 1H), 1.54 (brs, 2H), 1.32 (m, 1H), 1.19 (s, 3H) ppm. ¹³C NMR (50 MHz, CDCl₃): $\delta = 136.3$, 123.6 \square 72.2, 70.8, 43.8, 34.2, 27.3, 26.9, 26.4, 18.7 ppm. MS *m*/*z* (%): 169 (M⁺-1,4), 152 (13), 149 (4), 137 (16), 119 (11), 109 (59), 94 (57), 79 (60), 69 (34), 59 (100). Anal. Calcd. for C₁₀H₁₈O₂ (170.25): C, 70.55; H, 10.66%. Found: C, 70.38; H, 10.72%.

ACKNOWLEDGMENTS

Q.W. thanks Professor M. Vandewalle (University of Gent, Belgium), in whose laboratory part of this work was initiated.

REFERENCES

- (a). Carrea, G.; Ottolina, G.; Riva, S. Role of solvents in the control of enzyme selectivity in organic media. Trends in Biotech. 1995, *13* (2), 63–70; (b) Scuri, R.; Giannetti, P.; Paesano, A. 2-(2,3-Dihydro-5-acetoxy-4,6,7-tribenzofuranyl)acetic acid (IRFI-016)—a new antioxidant mucoactive drug. Drug Exp. Clin. Res. 1990, *16* (12), 649–656.
- 2. (a) Crowell, P.L. Monoterpenes in breast cancer chemoprevention. Breast Cancer Res. Treat. **1997**, *46* (2–3), 191–197; (b). Ellebgbed, J.A.;



2134

Wang, Li, and Chen

Maltzman, T.H.; Elson, C.E.; Gould, M.N. Effects of anticarcinogenic monoterpenes on phase-II hepatic metabolizing enzymes. Carcinogenesis **1993**, *14* (6), 1221–1223; (c). Crowell, P.L.; Kennan, W.S.; Haag, J.D.; Ahmad, S.; Vedejs, E.; Gould, M.N. Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of D-limonene. Carcinogenesis **1992**, *13* (7), 1261–1264; (d). Maltzman, T.H.; Christou, M.; Gould, M.N.; Jefcoate, C.R. Effects of monoterpenoids on in vivo DMBA-DNA adduct formation and on phase I hepatic metabolizing enzymes. Carcinogenesis **1991**, *12* (11), 2081–2087.

- 3. Touvay, C.; Vilain, B.; Carre, C.; Menciahuerta, J.M.; Braquet, P. Effect of limonene and sobrerol on monocrotaline-induced lung alterations and pulmonary-hypertension. Int. Arch Allergy Immunol. **1995**, *107* (1–3), 272–274.
- (a) William, F.E. The absolute configurations of the monoterpenes. In *Chemistry of the Monoterpenes an Encyclopedic Handbook*, Willian, F.E., Ed.; Marcel Dekker, Inc.: New York, 1985; 215–217; (b). William, F.E. The pinane monoterpenes. In *Chemistry of the Monoterpenes an Encyclopedic Handbook*; Willian, F.E., Ed.; Marcel Dekker, Inc.: New York, 1985; 969–971.
- Rothenberg, G.; Yatziv, Y.; Sasson, Y. Comparative autoxidation of 3-carene and alpha-pinene: factors governing regioselective hydrogen abstraction reactions. Tetrahedron 1998, 54 (3–4), 593–598.
- Manchand, P.S.; Towsend, J.M.; Belica, P.S.; Wong, H.S. A convenient synthesis of 3,5-dimethoxy-4-methylbenzoic acid. Synthesis 1980, (4), 409–410.
- Wang, P.; Adams, J. Model studies of the stereoelectronic effect in Rh(II) mediated carbenoid C-H insertion reactions. J. Am. Chem. Soc. 1994, 116 (8), 3296–3305.
- Medvedovici, A.; Sandra, P.; Toribo, L.; David, F. Chiral packed column subcritical fluid chromatography on polysaccharide and macrocyclic antibiotic chiral stationary phases. J. Chromatography A 1997, 785 (1–2), 159–171.
- 9. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis **1981**, (1), 1–28.
- 10. Mori, K.; Igarashi, Y.; Synthesis of the enantiomers of alphaphellandren-8-ol (*p*-menth-1,5-dien-8-ol), a monoterpene from bark beetles. Liebigs. Ann. Chem. **1988**, (1), 93–95.

Received in the USA September 16, 2002